おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Advanced BioHealing
company
About
Advanced BioHealing develops regenerative medicine solutions and commercializes cell-based and tissue-engineered products.
- 501 - 1000
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $25.50M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$25.50M
Advanced BioHealing has raised a total of
$25.50M
in funding over 2 rounds. Their latest funding was raised on
Feb 27, 2007 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 27, 2007 | Series C | $25.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Advanced BioHealing is funded by 1 investors.
Channel Medical Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Channel Medical Partners
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
